Cargando…
Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia
The treatment of patients with acute myeloid leukemia (AML) with targeted immunotherapy is challenged by the heterogeneity of the disease and a lack of tumor-exclusive antigens. Conventional immunotherapy targets for AML such as CD33 and CD123 have been proposed as targets for chimeric antigen recep...
Autores principales: | Laborda, Eduardo, Mazagova, Magdalena, Shao, Sida, Wang, Xinxin, Quirino, Herlinda, Woods, Ashley K., Hampton, Eric N., Rodgers, David T., Kim, Chan Hyuk, Schultz, Peter G., Young, Travis S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713229/ https://www.ncbi.nlm.nih.gov/pubmed/29077054 http://dx.doi.org/10.3390/ijms18112259 |
Ejemplares similares
-
Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
por: Koedam, Jan, et al.
Publicado: (2022) -
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
por: Fan, Mingxue, et al.
Publicado: (2017) -
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022) -
Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
por: Schorr, Christopher, et al.
Publicado: (2022) -
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)